I strongly suspect this is a run-up to Takeda's 27/1/13 NDA on NESINA. NESINA is already on sale in Japan and has a sales run-rate of $475m there. Furiex is entitled to a $25m milestone on US approval & royalties of 7%-12%.
This is also a resubmission as the FDA turned down the original NDA - as they wanted to see more safety data (given general nervousness over side-effect profiles of diabetes medicines). I'd give this 2nd NDA a very good chance of approval - as the FDA have narrowed their concerns to getting more safety data which Takeda included in their resubmission.
If this is approved, then I'd expect a pop to the $25-$30 price range. I'd sell out quick & come back in late 2013 for the MuDelta Phase III readout - probably due in Q1 14.